Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma
Clinical trial NCT06731803 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06731803
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-03-25
- Primary completion
- 2027-12-31
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.